Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

DIGITAL CONTENT

1 NEWS #PharmaBuzz

media
1 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

3DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Amg-650, 2410796-79-9, Amg 650 [who-dd], Op393m4h32, Benzamide, 2-(6-azaspiro(2.5)oct-6-yl)-n-(2-(4,4-difluoro-1-piperidinyl)-6-methyl-4-pyrimidinyl)-4-(((2-hydroxyethyl)sulfonyl)amino)-, Unii-op393m4h32

Molecular Formula

C₂₆H₃₄F₂N₆O₄S

Molecular Weight

564.6 g/mol

InChI Key

KBDGEJDIHZDPHN-UHFFFAOYSA-N

FDA UNII

OP393M4H32

Sovilnesib is an orally bioavailable, small-molecule inhibitor of the human kinesin-like protein KIF18A, with potential antineoplastic activity. Upon oral administration, sovilnesib selectively inhibits the activity of KIF18A. This may result in multipolar cell division and inhibit tumor cell proliferation. KIF18A, a mitotic kinesin-8 motor protein, plays an important role in the regulation of chromosome positioning during cell division and is overexpressed in certain cancers. Certain cancer cells with chromosomal instability (CIN) features depend on KIF18A activity for bipolar spindle integrity and cell proliferation.

1 2D Structure

Sovilnesib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-4-(2-hydroxyethylsulfonylamino)benzamide

2.1.2 InChI

InChI=1S/C26H34F2N6O4S/c1-18-16-22(31-24(29-18)34-12-8-26(27,28)9-13-34)30-23(36)20-3-2-19(32-39(37,38)15-14-35)17-21(20)33-10-6-25(4-5-25)7-11-33/h2-3,16-17,32,35H,4-15H2,1H3,(H,29,30,31,36)

2.1.3 InChI Key

KBDGEJDIHZDPHN-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=CC(=NC(=N1)N2CCC(CC2)(F)F)NC(=O)C3=C(C=C(C=C3)NS(=O)(=O)CCO)N4CCC5(CC5)CC4

2.2 Other Identifiers

2.2.1 UNII

OP393M4H32

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Amg-650

2. 2410796-79-9

3. Amg 650 [who-dd]

4. Op393m4h32

5. Benzamide, 2-(6-azaspiro(2.5)oct-6-yl)-n-(2-(4,4-difluoro-1-piperidinyl)-6-methyl-4-pyrimidinyl)-4-(((2-hydroxyethyl)sulfonyl)amino)-

6. Unii-op393m4h32

7. Chembl5084301

8. Schembl22119383

9. Us11236069, Example 4

10. Bdbm535532

11. Ex-a6760

12. Us11236069, Example 15

13. Nsc839866

14. Nsc-839866

15. Hy-132840

16. Cs-0204143

17. 2-(6-azaspiro[2.5]octan-6-yl)-n-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-4-(2-hydroxyethylsulfonylamino)benzamide

18. N-(2-(4,4-difluoropiperidin-1-yl)-6- Methylpyrimidin-4-yl)-4-((2- Hydroxyethyl)sulfonamido)-2-(6- Azaspiro[2.5]octan-6-yl)benzamide

2.4 Create Date

2020-08-12

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₃₄F₂N₆O₄S
Molecular Weight	564.6 g/mol
XLogP3	3.8
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	8
Exact Mass	g/mol
Monoisotopic Mass	g/mol
Topological Polar Surface Area	136
Heavy Atom Count	39
Formal Charge	0
Complexity	958
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1